Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. (13th August 2013)

• Record Type: Journal Article
• Authors: Safaee Ardekani, G.; Jafarnejad, S.M.; Khosravi, S.; Martinka, M.; Ho, V.; Li, G.
• Is Part Of: British journal of dermatology. Volume 169:Number 2(2013:Aug.)
• Page Start: 320
• Page End: 328
• Publication Date: 2013-08-13
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12351
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="short" xml:lang="en" id="bjd12351-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>What's already known about this topic?</bold> </p> <p> <list id="bjd12351-list-0001" list-type="bullet"> <list-item> <p>Mutations in <italic>BRAF</italic> have been reported in approximately 50% of melanomas, and BRAF inhibitors have shown promising results in early clinical trials.</p> </list-item> </list> </p> <p> <bold>What does this study add?</bold> </p> <p> <list id="bjd12351-list-0002" list-type="bullet"> <list-item> <p>Notwithstanding vast studies on <italic>BRAF</italic> mutations, the status of its protein expression has not been assessed during melanoma progression.</p> </list-item> <list-item> <p>We revealed BRAF protein expression to be a significant prognostic factor in the outcome for patients with melanoma.</p> </list-item> </list> </p> </abstract>